This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study (preprint)
medrxiv; 2022.
Preprint
in English
| medRxiv | ID: ppzbmed-10.1101.2022.04.16.22273762
ABSTRACT
Background Tuberculosis is a leading infectious cause of death worldwide. Novel vaccines will be required to reach global targets and reverse setbacks from the COVID-19 pandemic. We estimated the impact of novel tuberculosis vaccines in low- and middle-income countries (LMICs), under alternative delivery scenarios. Methods We calibrated a tuberculosis model to 105 LMICs (93% of global incidence). Vaccine scenarios were implemented as Basecase routine vaccination of 9-year-olds and a one-time vaccination campaign for ages ≥10 with country-specific introduction between 2028–2047 and 5-year scale-up to target coverage; Accelerated Scale-up as Basecase , but all countries introducing in 2025 with instant scale-up; and Routine Only as Basecase , but routine vaccination only. Vaccines protected against disease for 10-years, with 50% efficacy. Findings The Basecase scenario reduced tuberculosis incidence (19.5% [95% uncertainty range=18.3– 21.6%]) and mortality (20.6% [19.2–23.4%]) rates in 2050 and prevented 3.6 (3.3–3.9) million deaths before 2050, including 1.6 million in the WHO South-East Asian region. The Accelerated Scale-up scenario reduced tuberculosis incidence (25.2% [23.9–27.5%]), mortality (26.7% [25.2–29.9%]), and prevented 7.9 (7.3–8.5) million deaths. The Routine Only scenario reduced tuberculosis incidence (9.9% [9.0–11.6%]), mortality (9.9% [8.9–12.3%]), and prevented 1.1 (0.9–1.2) million deaths. Interpretations Novel tuberculosis vaccines could have substantial impact, which will vary depending on delivery strategy. Including a campaign will be crucial for rapid impact. Accelerated introduction, similar to the pace of COVID-19 vaccines, could approximately double the lives saved before 2050. Investment is required to support vaccine development, manufacturing, prompt introduction and scale-up. Funding WHO (2020/985800-0)
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Main subject:
Tuberculosis
/
COVID-19
Language:
English
Year:
2022
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS